Nervgen Pharma Corp (NGEN) Stock Price, Quote & News

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study....

Industry: Biotechnology

Sector: Healthcare

Phone: 778-731-1711

Website: www.nervgen.com

Address:

112-970 Burrard Street, Unit 1290, Vancouver, Canada

Mikavelli17 Apr. 8 at 12:37 AM

$NGEN Friends, please correct me if wrong. Does the fact that NGEN is collaborating with the FDA and integrating a specialized, "RESTORE" criteria within upcoming p3 trial not read as a potential rung in the dream ladder of AA? I am not a bio pharm expert but I would imagine the FDA does not often collaborate with a tiny start up, more or less requesting results of a certain style? Right? Typically on the bio pharm co. to design their own trials and present findings. Sink or swim. One of the reasons its hard to cross the finish line. Perhaps I am being overly optimistic but I don't view this as so bad. Was very unlike AA would be granted based on 10 patients. Perhaps FDA said.....ok ok prove it works in this fashion and we talk open label. @OculusPrime @aladdinscarpet @NVG291Fan

1 · Reply

aladdinscarpet Apr. 8 at 12:26 AM

$NGEN Boom‼️ It is Tuesday…

0 · Reply

aladdinscarpet Apr. 7 at 11:08 PM

$NGEN TACO rebound tomorrow

1 · Reply

OculusPrime Apr. 7 at 10:52 PM

$NGEN AA isn’t over. It just hasn’t been earned yet. Nervgen may still be working out or waiting on data details to build a stronger case and phase 3 doesn’t have to be completed to be granted AA. Phase 3 alignment actually strengthens a future AA case. As for why it may have been omitted from the PR, it might be because it’s something that is still in progress and undetermined at this point in time.

2 · Reply

TH3_PR0F1T Apr. 7 at 8:56 PM

$NGEN $NGEN You can name stocks that have done well. Can you name any that are primed for that kind of growth???

1 · Reply

shopno Apr. 7 at 8:23 PM

$NGEN 2x is peanut in biotech, where lots of regulatory and execution risk lies. Glad that I sold partially and still holds 10s of thousands. I will look to buyback in low $3 or who knows below that. Look TERN 1 year chart— 2500% to $7B BO . Even VRNA got 6-700% to $10B BO, and CDTX got over 500% in 5 months to $9B BO after the trial results. IBRX earlier this year got 600% boost alone. $NGEN has ling road ahead to get acquired at premium valuation, or to grow organically with flawless execution (I am not confident on current management on this latter route).

1 · Reply

TH3_PR0F1T Apr. 7 at 8:04 PM

$NGEN kwon what you own and why you own it!

0 · Reply

shopno Apr. 7 at 7:44 PM

$NGEN Stock nose diving hard on no update on AA pathway. It’s clear as daylight no AA in the discussion. Won’t surprise if NGEN goes below $3. I don’t blame management here, but retail junkies hyped up AA as guaranteed.

1 · Reply

MetalinMaybach Apr. 7 at 6:38 PM

$NGEN I think this ultimately gets approved, but this update also shows the reality, FDA wants a full Phase 3, no shortcut. They’re clearly prioritizing chronic and shelving subacute for now to focus resources, which makes sense, but it also means a longer timeline. One thing I’m curious about is how fast this PR came out. If the EOP2 meeting was late last month, this turnaround is quicker than the typical ~30 days. Makes me wonder if there’s more detail coming or if this was just the headline alignment. Also, subacute being deprioritized could be a double-edged sword. If that data isn’t as strong, it may not matter strategically, but it could still impact sentiment, especially if they need to raise capital before Phase 3 readout.

5 · Reply

BioTuesdays Apr. 7 at 5:57 PM

$NGEN has announced the completion of a successful end-of-Phase 2 (EOP2) meeting with the FDA and alignment on RESTORE, the company’s Phase 3 registrational study designed to evaluate NVG-291 for chronic tetraplegia. https://biotuesdays.com/2026/04/07/nervgen-completes-eop2-meeting-and-aligns-with-fda-on-phase-3-study/

0 · Reply

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

Mar 31, 2026, 7:45 AM EDT - 7 days ago

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

Mar 12, 2026, 4:15 PM EDT - 26 days ago

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

Mar 4, 2026, 7:30 AM EST - 4 weeks ago

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

Feb 18, 2026, 7:30 AM EST - 6 weeks ago

NervGen Pharma to Participate at Upcoming Investor Conferences

Feb 12, 2026, 4:15 PM EST - 7 weeks ago

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

Feb 11, 2026, 7:00 AM EST - 7 weeks ago

NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium

Feb 9, 2026, 7:00 AM EST - 2 months ago

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

Jan 8, 2026, 6:30 AM EST - 3 months ago

NervGen Pharma Begins Trading on Nasdaq Today

Dec 17, 2025, 4:18 PM EST - 3 months ago

NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Dec 12, 2025, 7:51 PM EST - 4 months ago

NervGen Pharma Announces Proposed Amendment to Warrants

Nov 24, 2025, 7:05 AM EST - 4 months ago

NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

Nov 24, 2025, 7:00 AM EST - 4 months ago

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

Nov 19, 2025, 4:26 PM EST - 4 months ago

NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Nov 18, 2025, 4:42 PM EST - 5 months ago

NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development

Aug 26, 2025, 7:30 AM EDT - 8 months ago

NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders

Aug 21, 2025, 7:30 AM EDT - 8 months ago

NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury

Jul 17, 2025, 7:30 AM EDT - 9 months ago

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion

Jul 7, 2025, 5:30 PM EDT - 9 months ago

NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update

Jul 3, 2025, 4:41 PM EDT - 9 months ago

NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth

Jul 1, 2025, 7:30 AM EDT - 10 months ago

NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones

Jun 18, 2025, 7:30 AM EDT - 10 months ago

NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role

May 21, 2025, 7:30 AM EDT - 11 months ago

NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting

May 16, 2025, 4:30 PM EDT - 11 months ago

NervGen Pharma Grants Stock Options

May 15, 2025, 7:30 AM EDT - 11 months ago

NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates

May 7, 2025, 7:30 AM EDT - 11 months ago

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

Apr 21, 2025, 7:30 AM EDT - 1 year ago

NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 9, 2025, 5:53 PM EDT - 1 year ago

NervGen Provides Quarterly "At-The-Market" Equity Program Update

Apr 3, 2025, 7:30 AM EDT - 1 year ago

NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates

Mar 31, 2025, 7:30 AM EDT - 1 year ago

NervGen Initiates Expanded Access Policy

Mar 25, 2025, 8:30 AM EDT - 1 year ago

NervGen Pharma to Host Virtual Investor Event

Mar 5, 2025, 8:30 AM EST - 1 year ago

NervGen Pharma to Present at the Virtual Life Science Investor Forum

Feb 6, 2025, 7:30 AM EST - 1 year ago

NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Jan 29, 2025, 5:00 PM EST - 1 year ago

NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 2, 2025, 7:30 AM EST - 1 year ago

NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Dec 20, 2024, 7:30 AM EST - 1 year ago

NervGen Announces "At-The-Market" Equity Program

Nov 14, 2024, 8:30 AM EST - 1 year ago

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Nov 7, 2024, 8:30 AM EST - 1 year ago

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Sep 30, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Sep 20, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Sep 16, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting

Aug 27, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 22, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates

Aug 6, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference

Jul 22, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma Appoints Neil Klompas to Board of Directors

Jun 25, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

Jun 20, 2024, 8:30 AM EDT - 1 year ago

NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium

May 17, 2024, 8:30 AM EDT - 2 years ago

NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting

May 16, 2024, 8:30 AM EDT - 2 years ago

NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates

May 7, 2024, 8:30 AM EDT - 2 years ago

NervGen Files Management Information Circular and Announces Board of Directors Transition

Mikavelli17 Apr. 8 at 12:37 AM

1 · Reply

aladdinscarpet Apr. 8 at 12:26 AM

$NGEN Boom‼️ It is Tuesday…

0 · Reply

aladdinscarpet Apr. 7 at 11:08 PM

$NGEN TACO rebound tomorrow

1 · Reply

OculusPrime Apr. 7 at 10:52 PM

2 · Reply

TH3_PR0F1T Apr. 7 at 8:56 PM

$NGEN $NGEN You can name stocks that have done well. Can you name any that are primed for that kind of growth???

1 · Reply

shopno Apr. 7 at 8:23 PM

1 · Reply

TH3_PR0F1T Apr. 7 at 8:04 PM

$NGEN kwon what you own and why you own it!

0 · Reply

shopno Apr. 7 at 7:44 PM

1 · Reply

MetalinMaybach Apr. 7 at 6:38 PM

5 · Reply

BioTuesdays Apr. 7 at 5:57 PM

0 · Reply

philmitchell Apr. 7 at 4:45 PM

$NGEN Now that they have a confirmed, approved trial design for a Phase 3 with the FDA and positive data from the completed chronic trial, big pharma can model out the costs and probability of success for NVG-291. If a partnership were to occur to fund Phase 3, it would likely happen between now and the start of the trial (according to the PR mid-2026 so June/July). If there is a small raise in the near term, that could be positive sign that they are working on a partnership and just want enough to get them through negotiations or to the specific point when funding would kick in.

1 · Reply

Lunasicc42 Apr. 7 at 4:39 PM

$NGEN I asked AI the definition of a 'registrational study' A registrational study (or registrational trial/registration trial) is not a formally defined regulatory term in FDA statutes, regulations, or a central glossary, but it is commonly used by the FDA, industry, and clinical researchers to refer to a clinical trial (typically Phase 2 or Phase 3) designed to generate sufficient safety and efficacy data to support a marketing application (e.g., NDA, BLA, or supplement) for FDA approval or to expand labeling for a new indication

0 · Reply

alexandredaigneault96 Apr. 7 at 3:29 PM

$NGEN everyone was patiently waiting FDA meeting announcement. Patiently waiting!! For what to tell us what we already know and the stock is now trading downwards. Lol .

1 · Reply

summer61 Apr. 7 at 2:31 PM

$NGEN I have always regarded the subacute trial as a way to hopefully shed some light on a preeminent question, what would happen if we can start this drug as soon as possible after injury? This has to be a pressing question in every injured patient's mind as well as every practicing physician. The difficulty with such a trial is that there may well be improvement during the first year following injury to nerves and that makes it difficult to measure natural improvement vs demonstrating medication-related benefit. But the question needs to have an attempt at response, and the subacute trial is not a waste of time and money. Whatever answer it gives has importance to many people.

1 · Reply

philmitchell Apr. 7 at 2:23 PM

$NGEN Also, the wrapping up of the subacute is the right strategic move. If it was taking longer to enroll then they need to conserve cash and focus efforts on the Phase 3. The data should still provide valuable insights on the effect of the drug on the subacute population and as they said in the press release can be used for a phase 3 trial design on subacute if necessary in the future.

0 · Reply

philmitchell Apr. 7 at 2:17 PM

$NGEN This is all very positive. With regard to AA, there is no way that it would have been given AA at this point. The FDA needs enrollment in the Phase 3 Trial to be at least underway and perhaps even fully enrolled before granting AA. Nervgen is right not to mention it and stay conservative in their comments. Recently, the FDA warned Dr. Patrick Soon-Shiong (ImmunityBio) about making overly positive remarks about his company’s cancer drug. And the design of the trial is very encouraging - needing only 150 participants, utilizing up to 60 sites for accessibility, larger target patient population than previous trial designs, and GRASSP as the primary endpoint.

0 · Reply

MetalinMaybach Apr. 7 at 1:56 PM

$NGEN I know we were all hoping to hear something about AA in this press release and unfortunately that wasn’t the case. It’s usually in these press releases that they’d mention it was still on the table. Frankly I’m shocked it wasn’t mentioned at all. Looks like we’ll need to complete a P3 trial before approval. The endpoint alignment is positive, sure. I’m also curious about the subacute data. They decided to just wrap it up? What a waste of money and time, but I guess it makes sense to focus all of their resources on what’s likely to be the winning goal. I was hoping for more but I guess this’ll do. Not too happy.

1 · Reply

aladdinscarpet Apr. 7 at 1:07 PM

$NGEN It could take a few days for the market to price today’s positive update. There is a lot of nuance here. Alignment with FDA on a single registrational trial is a big win IMO. We’ll see if institutions agree. ymmv.

2 · Reply

DND603 Apr. 7 at 12:31 PM

$NGEN Does the clinical end point seem to be a slam dunk given the success of the drug to date. Will it impair approval from drug companies for SCI indications not related to the grasp test ?

1 · Reply

Itinerant Apr. 7 at 12:24 PM

$NGEN I imagine that we will have some kind of financing needed for the P3 soon.

1 · Reply

Shivanzu Apr. 7 at 11:40 AM

$NGEN https://nervgen.com/nervgen-pharma-announces-successful-end-of-phase-2-meeting-and-fda-alignment-on-restore-a-phase-3-registrational-study-of-nvg-291-for-chronic-tetraplegia/

2 · Reply

DavesStockPicks Apr. 7 at 1:20 AM

$NGEN Once the SP is sustained above the$5 threshold it'll no longer be considered a penny stock. I imagine institutional investors will begin purchasing after that if they're watching closely. Some institutions have a policy of $10 and above only. It wouldn't take long to go from$5 to$10 if institutions begin piling in.

0 · Reply

Market Cap	N/A
Revenue (ttm)	46.92M
Net Income (ttm)	-38.10M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	0.00
Profit Margin	-81.20%
Debt to Equity Ratio	N/A

Volume	775,700
Avg Vol	145,364
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	80%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A